<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892020000200009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización de los anticuerpos anti-HLA en posibles receptores cubanos de trasplante cardiaco]]></article-title>
<article-title xml:lang="en"><![CDATA[Characterization of anti-HLA antibodies in Cuban possible receptors of heart transplant]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marcell Rodríguez]]></surname>
<given-names><![CDATA[Lelyem]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morera Barrios]]></surname>
<given-names><![CDATA[Luz M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ustariz García]]></surname>
<given-names><![CDATA[Catalino R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez Hernández]]></surname>
<given-names><![CDATA[Mahelys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nafeh Abi-rezk]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chang Monteagudo]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Clínico Quirúrgico &#8220;Hermanos Amejeiras&#8221;  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892020000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892020000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892020000200009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: En la supervivencia del corazón trasplantado son de importancia el empleo de los anticuerpos contra el sistema principal de histocompatibilidad (anticuerpos anti-HLA). Hace seis años se introdujo en Cuba el porcentaje de anticuerpos anti-HLA frente a panel (PRA) por método de ensayo de inmunoabsorción ligado a enzima (ELISA) como parte de las pruebas de compatibilidad pretrasplante de los receptores de trasplante cardiaco.  Objetivo: Caracterizar los anticuerpos anti-HLA en pacientes receptores cubanos de trasplante cardiaco.  Métodos: Entre septiembre de 2013 y abril de 2017 se les realizó el PRA por ELISA a 38 muestras de pacientes recibidas en el laboratorio de histocompatibilidad del Instituto de Hematología e Inmunología. Se utilizó la comparación de proporciones para el análisis estadístico.  Resultados: El 47,4 % de los pacientes estudiados presentó anticuerpos anti-HLA, fueron los más frecuentes los de clase I. La proporción de pacientes con PRA del 0 % fue mayor en PRA clase II que en I (p: 0,0027). Mientras que fue mayor la proporción de pacientes con PRA clase I entre el 20 y el 75 % (p: 0,0046). El 77,8 % de los pacientes tuvo un PRA clase I mayor al 10 % y en el PRA clase II alcanzó el 80 %.  Conclusiones:  El porcentaje de anticuerpos anti-HLA frente a panel por método de ensayo de inmunoabsorción ligado a enzima permitió una mejor caracterización de los anticuerpos anti-HLA, lo que contribuyó a mejorar la compatibilidad en este tipo de paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  In survival after heart transplantation, the use of antibodies against the main histocompatibility system (anti-HLA antibodies) is important. Six years ago, the percentage of anti-HLA antibodies against panel (PRA) by enzyme-linked immunosorbent assay (ELISA) method was introduced in Cuba as part of the pre-transplant compatibility tests of heart transplant recipients.  Objective:  To characterize anti-HLA antibodies in Cuban heart transplant recipients.  Methods:  Between September 2013 and April 2017, PRA by ELISA was performed on 38 patient samples received in the histocompatibility laboratory of the Institute of Hematology and Immunology. Comparison of proportions was used for statistical analysis.  Results:  47.4% of the study patients presented anti-HLA antibodies; those in class were the most frequent. The proportion of patients with PRA of 0% was higher in PRA class II than in class I (p=0.0027). The proportion of patients with PRA class I was greater, accounting for 20-75% (p=0.0046). 77.8% of the patients had a class I PRA greater than 10%, while in class II PRA it reached 80%.  Conclusions:  The percentage of anti-HLA antibodies versus a panel of enzyme linked immunosorbent assay method allowed better characterization of anti-HLA antibodies, which contributed to improving compatibility in this type of patient.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[anticuerpos anti-HLA]]></kwd>
<kwd lng="es"><![CDATA[trasplante cardiaco]]></kwd>
<kwd lng="es"><![CDATA[método de ensayo de inmunoabsorción ligado a enzima (ELISA)]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos frente a panel (PRA)]]></kwd>
<kwd lng="en"><![CDATA[anti-HLA antibodies]]></kwd>
<kwd lng="en"><![CDATA[heart transplantation]]></kwd>
<kwd lng="en"><![CDATA[enzyme linked immunosorbent assay (ELISA) method]]></kwd>
<kwd lng="en"><![CDATA[antibodies versus panel (PRA)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamorano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sepúlveda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trasplante cardíaco]]></article-title>
<source><![CDATA[Rev Hosp Clín Univ Chile]]></source>
<year>2007</year>
<volume>18</volume>
<page-range>299-309</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kittleson]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changing Role of Heart Transplantation]]></article-title>
<source><![CDATA[Heart Fail Clin]]></source>
<year>2016</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>411-21</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero Cabrera]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insuficiencia cardiaca en el anciano Un problema no resuelto]]></article-title>
<source><![CDATA[Medisur]]></source>
<year>2004</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>72-85</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soler Morejón]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insuficiencia cardiaca: una causa importante de muerte]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Mesquia de Pedro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cub Med]]></source>
<year>2014</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>359-62</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Anuario estadístico de salud]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of allosensitized cardiac transplant candidates]]></article-title>
<source><![CDATA[Transplant Rev]]></source>
<year>2009</year>
<volume>23</volume>
<page-range>235-47</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kobashigawa J]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[West]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kerman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zeevi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reinsmoen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation]]></article-title>
<source><![CDATA[J Heart Lung Transplant]]></source>
<year>2009</year>
<volume>28</volume>
<page-range>213-25</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Mohaissen MA]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kaan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kealy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Virani]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Successful 4S Heart Transplantation]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2011</year>
<volume>27</volume>
<page-range>679-81</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barten]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Beiras-Fernandez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berchtold-Herz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Boeken]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Garbade]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hirt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical impact of donorspecific antibodies in heart transplantation]]></article-title>
<source><![CDATA[Transplant Rev]]></source>
<year>2018</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>207-17</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conway]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dipchand]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Challenges with sensitized recipients in pediatric heart transplantation]]></article-title>
<source><![CDATA[Clinics]]></source>
<year>2014</year>
<volume>69</volume>
<numero>S1</numero>
<issue>S1</issue>
<page-range>17-21</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reinsmoen]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Mirocha]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Naim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens]]></article-title>
<source><![CDATA[J Heart Lung Transplant]]></source>
<year>2016</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>165-72</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connor]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pahl]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Webber]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Rossano]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in heart transplant immunology: The role of antibodies]]></article-title>
<source><![CDATA[Progress in Pediatric Cardiology]]></source>
<year>2016</year>
<volume>43</volume>
<page-range>81-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<source><![CDATA[Immucor GTI Diagnostics Inc]]></source>
<year></year>
<publisher-name><![CDATA[LIFECODES QuikScreen for in vitro diagnostic use(package insert); LIFECODES B-Screen for in vitro diagnostic use (package insert), Waukesha, WI; LIFECODES Quik-ID Class I for in vitro diagnostic use (package insert); LIFECODES Quik-ID Class II for in vitro diagnostic use (package insert)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schumacher KR]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Kamoun]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caruthers]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gajarski]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HLA desensitization in pediatric heart transplant candidates Efficacy of rituximab and IVIg]]></article-title>
<source><![CDATA[J Heart Lung Transplant]]></source>
<year>2012</year>
<volume>31</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1041-2</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marcell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ustariz]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Bencomo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Método cubano para determinar el porcentaje calculado de anticuerpos reactivos contra panel]]></article-title>
<source><![CDATA[Rev Cub Hematol Inmunol Hemoter]]></source>
<year>2018</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>41-3</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodey GE]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Whelchel]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Revels]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epitope specificity of HLA class I alloantibodies I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients]]></article-title>
<source><![CDATA[Hum Immunol]]></source>
<year>1994</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>272-80</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ustariz]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Costales]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bencomo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identificación de anticuerpos anti-HLA en pacientes en espera de trasplante renal]]></article-title>
<source><![CDATA[Rev Cub Hematol Inmunol Hemoter]]></source>
<year>2015</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>138-49</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
